There has recently been news of a new drug in the pipeline for SJIA, the childhood form of Still’s Disease, which should offer us some hope also. So far, reports claim the drug is particularly effective in treating SJIA and has allowed patients to reduce their steroids by up to 45%. Canakinumab, otherwise known as Ilaris, is manufactured by Novartis and is an Interleukin-1 inhibitor.
I’ll post the articles that I have received today, as they all make for interesting reading:
Ilaris Helps Childhood Arthritis – Reuters
Could be promising?